Business Wire

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

22.4.2025 20:00:00 CEST | Business Wire | Press release

Share

Debiopharm announces oral and poster presentations on data from their potential first-in-class compound Debio 1562M, a CD37-targeted ADC, and their best-in-class compound Debio 0123, a brain-penetrant WEE1 inhibitor. The company also announces joint poster presentation with new partner on the use of its AbYlink™ technology in preclinical setting.

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases and develop new antibody linker technologies, will release promising new data for two of its pipeline products at the 2025 Annual American Association for Cancer Research (AACR) meeting in Chicago, Illinois. Furthermore, a joint poster presentation with Oncodesign Services (www.oncodesign-services.com) will highlight the applicability of its antibody conjugation technology, AbYlink™, in the preparation of conjugates for use in non-invasive preclinical imaging.

Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human evaluation. Two preclinical data releases will be included in the poster display sessions for Debio 0123, a selective WEE1 kinase inhibitor disrupting the DNA-damage response (DDR) of cancer cells. The first data release shows how Debio 0123 can be used in combination with the PKMYT1 inhibitor lunresertib as a promising therapeutic strategy in ovarian and breast cancer. The company will also unveil new impactful findings stemming from its collaboration with Genialis, showing how machine learning has the potential to enhance the ability to predict responders to Debio 0123, thus further advancing the understanding and application of WEE1 biology and response to inhibitors.

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how AbYlink™ conjugation technology can facilitate the production of conjugates for use in preclinical research in cancer treatment.

“The pre-clinical results to be released during the AACR are laying a solid foundation for future research,” explained Angela Zubel, Chief Development Officer, Debiopharm. “The two drug research approaches of ADCs and DDR inhibition are harnessing novel modalities and targets with the potential to outsmart hard-to-treat liquid and solid tumors, revolutionizing patient outcomes. Our AbYlink™ technology demonstrates great potential in the context of antibody radio conjugates against cancer and shows promise for broader use and wider applications.”

  • Session Title: Antibody-Based Cancer Therapeutic Agents

AACR 2025
Oral Presentation

Debiopharm compound

Title

Presenter

-Sun, April 27th

-Mini symposium: 3:35-3:50pm

-Abstract Presentation #: 1160 

Debio 1562M

Debio 1562M, a 2nd generation ADC targeting CD37, shows high potency against AML and MDS and safe toxicological profile for future clinical development

Lisa Ivanschitz, Associate Principal Scientist, Debiopharm

  • Poster Session Title: DNA Damage Response and Modulation of DNA Repair 1

AACR 2025
Poster Presentation

Debiopharm compound

Title

Presenter

-Mon, April 28th

-Poster display: 2:00-5:00pm

-Abstract #2914

-Poster Section: 16

-Poster Board #: 21

Debio 0123

The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer

Luke Piggott, Principal Scientist, Debiopharm

  • Poster Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery

AACR 2025
Poster Presentation

Debiopharm compound

Title

Presenter

-Mon, April 28th

-Poster display: 2:00-5:00pm

-Abstract #3659

-Poster Section: 45

-Poster Board #: 21

Debio 0123

Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123

Kristian Urh, Genialis

  • Poster Session Title: Radiation Treatment Combinations for Tumors, Normal Tissue

AACR 2025
Poster Presentation

Debiopharm technology

Title

Presenter

-Mon, April 28th

-Poster display: 9:00am-12:00pm

-Abstract #1825

-Poster Section: 24

-Poster Board #: 11

AbYlink™

Pharmacological evaluation of bioconjugated Trastuzumab using the AbYlink™ regio-selective conjugation technology in gastric cancer expressing HER2+

Eftychia Koumarianou, Head of pharmaco-imaging and molecular radiotherapy, Oncodesign Services

About DNA-Damage Repair (DDR)

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debio 0123, a WEE1 inhibitor from Debiopharm, are being tested in clinical and preclinical studies.

Debiopharm’s ADC portfolio

We’re developing fit-for-purpose antibody drug conjugates through a tailored “Trifecta” approach: strategic target selection, innovative Multilink™ linker technology and smart payload choices. Our broad and balanced portfolio of 1st-in-class and best-in-class ADCs includes Debio 0633 (undisclosed target), Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) Myelodysplastic syndromes (MDS), Debio 0532, an HER3-targeted ADC for solid tumors, as well as other ADCs for undisclosed targets including a proprietary bispecific ADC. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other antibodies for undisclosed targets. To allow both high DAR and high stability, our ADCs are designed with our innovative proprietary Multilink™ linker technology. We’re leveraging key collaborations and our in-house capabilities including ADC conjugation, optimization, PK/PD, toxicology, translational medicine, clinical development and supply chain to produce novel ADCs that respond to the high unmet needs of cancer patients.

About AbYlink™

AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g. a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.

Debiopharm’s commitment to cancer patients

Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential assets and technologies for in- licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.

Visit us www.debiopharm.com/drug-development/ and www.debiopharm.com/manufacturing-science

Follow us

https://www.linkedin.com/company/debiopharminternational/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422765289/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release

Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release

Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release

Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye